Scholarlink

<p>Targeting glucose metabolism has long been pursued as an anticancer strategy, yet its clinical translation remains challenging. Achieving therapeutic selectivity requires identifying actionable metabolic distinctions between different malignant traits. Here, we uncover a noncanonical, lactate-independent glucose metabolic pathway facilitated by the glucose transporter 6 (GLUT6), which confers targeted therapy resistance in lung cancer. Downstream, GLUT6 promotes glucose influx and diversion toward methylglyoxal production, leading to kelch-like ECH-associated protein 1 (KEAP1) dimerization and nuclear factor erythroid 2-related factor 2 (NRF2) pathway activation, driving resistance. Upstream, GLUT6 expression is transcriptionally upregulated by therapy-induced MYC associated zinc finger protein (MAZ) activation. Targeting GLUT6 prevents and overcomes EGFR and KRAS inhibitors resistance. Moreover, the MAZ–GLUT6–NRF2 axis correlates with clinical treatment response and relapse. The preferential reliance on GLUT6—a noncanonical transporter with minimal systemic homeostasis perturbation—highlights its promise as a target for overcoming resistance and revitalizing glucose metabolism–based anticancer strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Huimin Lei,
  • Ruixue Xia,
  • Yabin Tang,
  • Jun Lu,
  • Chan Xiang,
  • Yujing Li,
  • Hongyu Liu,
  • Peichen Zou,
  • Ayinazhaer Aihemaiti,
  • Wei Zhang,
  • Ying Shen,
  • Baohui Han,
  • Yuchen Han,
  • Hua Zhong,
  • Hongzhuan Chen,
  • Liang Zhu

摘要

Targeting glucose metabolism has long been pursued as an anticancer strategy, yet its clinical translation remains challenging. Achieving therapeutic selectivity requires identifying actionable metabolic distinctions between different malignant traits. Here, we uncover a noncanonical, lactate-independent glucose metabolic pathway facilitated by the glucose transporter 6 (GLUT6), which confers targeted therapy resistance in lung cancer. Downstream, GLUT6 promotes glucose influx and diversion toward methylglyoxal production, leading to kelch-like ECH-associated protein 1 (KEAP1) dimerization and nuclear factor erythroid 2-related factor 2 (NRF2) pathway activation, driving resistance. Upstream, GLUT6 expression is transcriptionally upregulated by therapy-induced MYC associated zinc finger protein (MAZ) activation. Targeting GLUT6 prevents and overcomes EGFR and KRAS inhibitors resistance. Moreover, the MAZ–GLUT6–NRF2 axis correlates with clinical treatment response and relapse. The preferential reliance on GLUT6—a noncanonical transporter with minimal systemic homeostasis perturbation—highlights its promise as a target for overcoming resistance and revitalizing glucose metabolism–based anticancer strategies.